ArticleFrontiers in medicine2021
Oridonin Alleviates LPS-Induced Depression by Inhibiting NLRP3 Inflammasome
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- The NLRP3 Inflammasome in Neuropsychiatric Disorders: Molecular Mechanisms and Emerging Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Astrocytes: Unveiling their role in the molecular mechanism of natural antidepressants.Journal of pharmaceutical analysis · 2026Review
- FGF2 alleviates LPS-induced acute lung injury by inhibiting ferritinophagy-mediated ferroptosis in AT2 cells via the Hippo-YAP signaling pathway.Frontiers in immunology · 2026Article
- Pharmacological mechanisms of natural products with antidepressant effects: A focus on the programmed cell death regulation.Journal of pharmaceutical analysis · 2026Review
- Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome.BMC gastroenterology · 2025Article
- Treatment of Parkinson's Disease with an Anti-Inflammasome NLRP3 Inhibitor Derived from a Natural Product.ACS pharmacology & translational science · 2025Article
- Molecular Mechanism of Antidepressant Effects of Active Ingredients in Traditional Chinese Medicine: The Role of Autophagy.Alpha psychiatry · 2025Review
- Review
- Article
- Therapeutic effects ofFrontiers in pharmacology · 2025Article
- Mitochondria in depression: The dysfunction of mitochondrial energy metabolism and quality control systems.CNS neuroscience & therapeutics · 2024Review
- Gypenoside-14 Reduces Depression via Downregulation of the Nuclear Factor Kappa B (NF-kB) Signaling Pathway on the Lipopolysaccharide (LPS)-Induced Depression Model.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Oridonin supplementation attenuates atherosclerosis via NLRP-3 inflammasome pathway suppression.Journal of medicine and life · 2023Article
- Targeting mitophagy for depression amelioration: a novel therapeutic strategy.Frontiers in neuroscience · 2023Review
- Antidepressant pharmacological mechanisms: focusing on the regulation of autophagy.Frontiers in pharmacology · 2023Review
- Resveratrol alleviates lipopolysaccharide-induced liver injury by inducing SIRT1/P62-mediated mitophagy in gibel carp (Frontiers in immunology · 2023Article
- Thymol Alleviates LPS-Induced Liver Inflammation and Apoptosis by Inhibiting NLRP3 Inflammasome Activation and the AMPK-mTOR-Autophagy Pathway.Nutrients · 2022Article
- Receptor-Interacting Protein Kinase 3 Suppresses Mitophagy ActivationFrontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.